TrialRMD open2024

Efficacy and safety of CT-P47 versus reference tocilizumab: 32-week results of a randomised, active-controlled, double-blind, phase III study in patients with rheumatoid arthritis, including 8 weeks of switching data from reference tocilizumab to CT-P47.

Josef S Smolen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.